821 results on '"Finazzi, Guido"'
Search Results
2. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
3. Polycythaemia vera
4. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
5. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th International Post-ASH Symposium
6. Evaluation of the Virulence Potential of Listeria monocytogenes through the Characterization of the Truncated Forms of Internalin A
7. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
8. Thrombocytosis and Essential Thrombocythemia
9. Contributors
10. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
11. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
12. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
13. Molecular characterization of Yersinia enterocolitica strains to evaluate virulence associated genes.
14. Contamination Source Identification for Prompt Management of a Gastroenteritis Outbreak Caused by Norovirus in Drinking Water in Northern Italy
15. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
16. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
17. Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
18. Prefibrotic myelofibrosis: treatment algorithm 2018
19. Newly Designed Primers for the Sequencing of the inlA Gene of Lineage I and II Listeria monocytogenes Isolates
20. Risk Classification
21. Therapy of Polycythemia Vera and Essential Thrombocythemia
22. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
23. Preparation of Powdered Infant Formula: Could Productʼs Safety Be Improved?
24. Essential Thrombocythemia
25. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study
26. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
27. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
28. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
29. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
30. Direct oral anticoagulants in rare venous thrombosis
31. Is SARS-CoV-2 a Concern for Food Safety? A Very Low Prevalence from a Food Survey during the COVID-19 Pandemic in Northern Italy
32. Myeloproliferative neoplasms and thrombosis
33. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera
34. Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients
35. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
36. The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
37. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
38. Front-line therapy in polycythemia vera and essential thrombocythemia
39. Foodborne botulism survey in Northern Italy from 2013 to 2020: Emerging risk or stable situation?
40. Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review
41. Are MPNs Vascular Diseases?
42. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
43. Thrombosis in primary myelofibrosis: incidence and risk factors
44. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
45. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
46. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
47. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
48. Management of special conditions in patients on vitamin K antagonists
49. Special Issues in Myeloproliferative Neoplasms
50. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.